The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Topological heterogeneity of genomic and immunologic effects from combination immunotherapy treatment in the neoadjuvant setting for renal cell carcinoma (RCC).
 
Tyler Alban
No Relationships to Disclose
 
Salendra Singh
No Relationships to Disclose
 
Paul G. Pavicic
No Relationships to Disclose
 
Patricia A. Rayman
No Relationships to Disclose
 
Prerana Parthasarathy Bangalore
No Relationships to Disclose
 
Amit Rupani
No Relationships to Disclose
 
Vladimir Makarov
No Relationships to Disclose
 
Christopher Przybycin
No Relationships to Disclose
 
Jennifer S. Ko
No Relationships to Disclose
 
Venkatesh Krishnamurthi
No Relationships to Disclose
 
Steven Campbell
Honoraria - FujiFlms
 
Timothy An-thy Chan
Leadership - Bristol-Myers Squibb; Cancer Genetics; Illumina
Stock and Other Ownership Interests - Gritstone Bio
Honoraria - Illumina
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Illumina; LG Chem; Pfizer
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Nysnobio (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigen discovery and genomic biomarkers for immunotherapy response
 
Brian I. Rini
Leadership - MashupMD; MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - Alkermes; Aravive; Arrowhead Pharmaceuticals; Athenex; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Debiopharm Group; Eisai; EUSA Pharma; Genentech; HiberCell; Merck; NiKang Therapeutics; Pfizer; Surface Oncology
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Dracen (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Point Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Stata (Inst); Surface Oncology (Inst); Vasgene Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
C. Marcela Diaz-Montero
No Relationships to Disclose
 
Moshe Chaim Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Aravive (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer